A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2016
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors GNT Pharma
- 21 Nov 2016 Status changed from active, no longer recruiting to completed.
- 23 Feb 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 23 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.